Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Position Increased by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC increased its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 4.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 135,749 shares of the company’s stock after acquiring an additional 6,177 shares during the period. Orion Portfolio Solutions LLC owned about 0.05% of Maravai LifeSciences worth $1,128,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Creative Planning raised its holdings in shares of Maravai LifeSciences by 4.4% during the third quarter. Creative Planning now owns 44,943 shares of the company’s stock worth $373,000 after acquiring an additional 1,881 shares in the last quarter. Kornitzer Capital Management Inc. KS raised its holdings in shares of Maravai LifeSciences by 0.7% during the third quarter. Kornitzer Capital Management Inc. KS now owns 519,890 shares of the company’s stock worth $4,320,000 after acquiring an additional 3,725 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Maravai LifeSciences during the second quarter worth $32,000. Liontrust Investment Partners LLP increased its position in Maravai LifeSciences by 14.7% during the second quarter. Liontrust Investment Partners LLP now owns 43,845 shares of the company’s stock worth $314,000 after buying an additional 5,628 shares during the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in Maravai LifeSciences during the third quarter worth $47,000. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Carl Hull bought 175,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average cost of $5.64 per share, with a total value of $987,000.00. Following the completion of the transaction, the insider now directly owns 175,000 shares in the company, valued at $987,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.63% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

MRVI has been the topic of several analyst reports. Robert W. Baird lowered their target price on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. William Blair reissued a “market perform” rating on shares of Maravai LifeSciences in a research report on Friday, November 8th. Wells Fargo & Company initiated coverage on shares of Maravai LifeSciences in a research report on Tuesday, August 27th. They set an “overweight” rating and a $10.00 target price on the stock. Wolfe Research initiated coverage on shares of Maravai LifeSciences in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Finally, Royal Bank of Canada lowered their target price on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Maravai LifeSciences presently has a consensus rating of “Hold” and an average price target of $10.28.

Maravai LifeSciences Trading Up 0.2 %

Shares of NASDAQ:MRVI opened at $5.67 on Friday. The company has a market cap of $1.43 billion, a P/E ratio of -3.46 and a beta of -0.08. The stock’s 50-day moving average is $6.52 and its 200-day moving average is $7.74. Maravai LifeSciences Holdings, Inc. has a 52-week low of $4.28 and a 52-week high of $11.56. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.